0JBU Stock Chart & Stats
$10.90
-$0.04(-0.37%)
At close: 4:00 PM EDT
$10.90
-$0.04(-0.37%)
Day’s Range― - ―
52-Week Range$7.91 - $28.33
Previous CloseN/A
Volume24.00
Average Volume (3M)30.08K
Market Cap
$1.49B
Enterprise Value$1.22K
Total Cash (Recent Filing)$375.99M
Total Debt (Recent Filing)$80.49M
Price to Earnings (P/E)―
Beta1.24
Next Earnings
Nov 05, 2026EPS Estimate
-0.79Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.54
Shares Outstanding139,722,270
10 Day Avg. Volume22,676
30 Day Avg. Volume30,080
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)1.45
Price to Sales (P/S)14.40
P/FCF Ratio-2.75
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$18.92Price Target Upside73.55% Upside
Rating ConsensusHold
Number of Analyst Covering14
EPS Forecast (FY)-3.2
Revenue Forecast (FY)$58.15M
Bulls Say, Bears Say
Bulls Say
Phase III Lonvo‑z Efficacy & Regulatory ProgressClear, statistically robust Phase III efficacy and an active rolling BLA create a durable pathway to approval and commercialization. A one‑time, first‑in‑class therapy can reshape the HAE treatment paradigm, support payer engagement and sustain long‑term market positioning if approved.
Nex‑z Potent, Rapid & Durable BiologyRobust, rapid, and durable target knockdown demonstrates strong mechanism validity and de‑risking of the modality for ATTR indications. Durable biological effect from a one‑time treatment supports differentiated clinical value and a sustainable competitive edge if Phase III confirms benefit.
Strengthened Balance Sheet And RunwayA larger cash balance and recent financing materially extend runway through key regulatory and commercial milestones, reducing near‑term funding risk. This allows completion of registrational programs and pre‑launch investments without immediate dilution pressure, improving execution optionality.
Bears Say
Persistent Negative Cash Flow And BurnSustained negative operating and free cash flow means the company must repeatedly access capital or partnerships to fund operations. Over time this elevates dilution risk, constrains discretionary R&D or commercial investments, and makes long‑term planning contingent on external financing availability.
Profitability & Gross Margin DeteriorationA negative trailing gross profit signals an adverse revenue mix or rising program costs, complicating the path to sustainable margins after launch. Persistent deep operating losses increase reliance on financing and heighten execution pressure to achieve profitable product economics post‑commercialization.
Nex‑z Safety Signal And HLA Subgroup ComplexityAn immune‑associated liver enzyme signal and an HLA‑linked subgroup create lasting regulatory, clinical trial and commercialization complexity. They can force pre‑screening, limit addressable patients, raise monitoring costs and prompt stricter label/REMS requirements even if efficacy remains strong.
Intellia Therapeutics News
0JBU FAQ
What was Intellia Therapeutics Inc’s price range in the past 12 months?
Intellia Therapeutics Inc lowest share price was $7.91 and its highest was $28.33 in the past 12 months.
What is Intellia Therapeutics Inc’s market cap?
Intellia Therapeutics Inc’s market cap is $1.49B.
When is Intellia Therapeutics Inc’s upcoming earnings report date?
Intellia Therapeutics Inc’s upcoming earnings report date is Nov 05, 2026 which is in 90 days.
How were Intellia Therapeutics Inc’s earnings last quarter?
Intellia Therapeutics Inc released its earnings results on Aug 06, 2026. The company reported -$0.8 earnings per share for the quarter, missing the consensus estimate of -$0.799 by -$0.001.
Is Intellia Therapeutics Inc overvalued?
According to Wall Street analysts Intellia Therapeutics Inc’s price is currently Undervalued.
Does Intellia Therapeutics Inc pay dividends?
Intellia Therapeutics Inc pays a Notavailable dividend of $0.285 which represents an annual dividend yield of N/A. See more information on Intellia Therapeutics Inc dividends here
What is Intellia Therapeutics Inc’s EPS estimate?
Intellia Therapeutics Inc’s EPS estimate is -0.79.
How many shares outstanding does Intellia Therapeutics Inc have?
Intellia Therapeutics Inc has 139,722,270 shares outstanding.
What happened to Intellia Therapeutics Inc’s price movement after its last earnings report?
Intellia Therapeutics Inc reported an EPS of -$0.8 in its last earnings report, missing expectations of -$0.799. Following the earnings report the stock price went up 2.71%.
Which hedge fund is a major shareholder of Intellia Therapeutics Inc?
Currently, no hedge funds are holding shares in GB:0JBU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Intellia Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$18.92 (73.55% Upside)
$18.92 (73.55% Upside)
Blogger Sentiment
Bullish
GB:0JBU Sentiment 64%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $135.6K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-16.04%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-23.06%
Trailing 12-Months
Company Description
Intellia Therapeutics Inc
Intellia Therapeutics, Inc. is a biotechnology firm dedicated to advancing therapeutic treatments through its expertise in genome editing. The company's pipeline includes several in vivo (administered within the body) programs. NTLA-2001 is currently undergoing a Phase 1 clinical trial for transthyretin amyloidosis, while NTLA-2002 targets hereditary angioedema. Additionally, Intellia is developing various other liver-focused therapies for conditions such as hemophilia A and B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo (processed outside the body) pipeline features NTLA-5001, a candidate for acute myeloid leukemia. The company is also progressing proprietary programs focused on creating engineered cell therapies to address diverse oncological and autoimmune disorders. At the core of Intellia's technology is the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has established multiple licensing and collaboration agreements. These include a partnership with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for treating sickle cell disease, and a co-development agreement with Regeneron Pharmaceuticals, Inc. for potential products against hemophilia A and B. The company also collaborates with Ospedale San Raffaele and holds a strategic alliance with SparingVision SAS to develop novel genomic medicines for ocular diseases, leveraging CRISPR/Cas9 technology. The company, initially known as AZRN, Inc., was founded in 2014 and operates from its headquarters in Cambridge, Massachusetts.
0JBU Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong, concrete clinical progress — most notably the unequivocal Phase III success for lonvo‑z (87% attack reduction, 62% attack‑free and therapy‑free, favorable safety) and compelling nex‑z biological data (≈90% TTR knockdown, rapid and durable) — alongside active regulatory and commercial preparations. Financially, the company strengthened its cash position with a ~$195M financing and maintains a runway into at least 2028, although collaboration revenue declined and G&A rose as commercial build‑out continues. The primary concern is a nex‑z liver enzyme safety signal and the identification of an HLA C*05:01 subgroup (~12% of samples) associated with higher Grade 3+ transaminase events; the company has implemented mitigation, added HLA typing to protocols, and is engaging regulators. Overall, the positive clinical milestones and clear mitigation plan for the safety finding outweigh the operational and financial headwinds discussed.View all GB:0JBU earnings summaries0JBU Revenue Breakdown
100.00% Collaboration revenue
0JBU Stock 12 Month Forecast
Average Price Target
$18.92
▲(73.55% Upside)
Technical Analysis
Kura Oncology
―
Compass Therapeutics
―
AbCellera Biologics
―
Janux Therapeutics Inc
―
Bicara Therapeutics Inc.
―